The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency

Secondary Immune Deficiency Clinical Trial

Official title:
Effect of Subcutaneous Immunoglobulin (IgSC) Gammanorm® on the Distribution of IgG Subclasses and on the Humoral Immunity of Patients With Secondary Immunodeficiency.

Status Completed

Clinical Trial Summary

Patients with Myeloma or CLL with severe secondary hypogammaglobinemia and recurrent infections will be included in this study; for whom an IgSC treatment was prescribed. The IgSC prescription will be the decision of the treating physician. Patient care and follow up will be performed according to the current clinical practice and the recommendations of HAS.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03369301
Study type	Observational
Source	Octapharma
Contact
Status	Completed
Phase
Start date	September 25, 2017
Completion date	November 22, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02711228` - Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules	Phase 4
Completed	`NCT03250845` - Comparison of Multigam IV (5% vs. 10%) in Patients With an Immunodeficiency Secondary to a Hematological Disorder
Completed	`NCT03211065` - Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig	Phase 2/Phase 3
Completed	`NCT03054181` - Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO)
Recruiting	`NCT04354129` - Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency.